Alberto Bardelli

From Wikitia
Jump to navigation Jump to search
Alberto Bardelli
Add a Photo
Born29 November 1967
NationalityItalian
CitizenshipItaly
Occupation
  • Geneticist
  • Cancer researcher
  • Expert in the field of precision medicine

Alberto Bardelli (Torino, 29 November 1967) is an Italian geneticist and cancer researcher, expert in the field of precision medicine. Full Professor of Histology at University of Turin|University of Torino and Director of the Laboratory of Molecular Oncology at Candiolo Cancer Institute FPO-IRCCS, Candiolo (TO), Italy.

Carrer

Alberto Bardelli was born in Turin|Torino on 29 November 1967. He studied Biological Sciences at the University of Torino and received his master's degree in 1991. After graduation, he moved to the Ludwig Institute for Cancer Research in London and obtained a PhD in Biochemistry and Molecular Biology from the University College London (UCL).

From 1999 to 2004 Bardelli has been postdoctoral researcher at the Johns Hopkins University School of Medicine and the Howard Hughes Medical Institute, Baltimore (MD/USA), in the group led by Prof. Bert Vogelstein. Here Bardelli began studying the genomics of cancer. During his postdoctoral training at the Johns Hopkins, Bardelli published multiple papers in high profile journals such as Nature and Science.

In 2004 he returned to Italy as director of a research unit dedicated to the study of tumour genomes at the Candiolo Cancer Institute and Dept. of Oncology, University of Torino.

Since 2016 he is Full Professor of Histology at University of Turin.[1][2]

From 2018 to 2020 he has been President of the European Association for Cancer Research (EACR).

He is member of the scientific committee of the Italian Association for Cancer Research (AIRC).[3]

In 2005 he was co-founder of the gene editing company Horizon Discovery.

Research

Alberto Bardelli performed the first comprehensive mutational profile of kinases in colorectal cancers (CRC)[4] and he has then translated these findings into clinical practice by discovering the molecular landscape of response and resistance to EGFR,[5][6] HER2[7] and NTRK1[8] blockade in CRC. One of the main focus of his research is the study of the emergence and evolution of drug-resistant clones that can be restrained to improve the efficacy of anticancer agents to develop therapies that adapt to tumour’s evolution.[9][10][11] To achieve this goal, his group leveraged integrated approaches including: genetic analysis of clinical samples, a large collection of CRC cellular models,[12] patient derived xenografts (xenopatients) and liquid biopsies, an innovative methodology to monitor the genotype of tumours in the blood of patients.[13][14][15][16] In the last years his studies uncovered the molecular bases of primary and acquired resistance to anti-EGFR therapies in colorectal tumours. These findings have been rapidly translated into clinically applicable predictive biomarkers, which are currently used to select patients for therapy and represent the first example of personalized medicine for colorectal tumours.[17]

Moreover Bardelli investigated the use of immunotherapy as tool for precision medicine in CRC. His studies are built on an unconventional approach that an increased dynamic and mutational load in CRC cells can rouse an otherwise slack immune response, a vital requisite for effective immunosurveillance. So Bardelli’s team tweaked the clonal evolution of the tumour, via a pharmacological intervention, to provoke the persistent renewal of neoantigens.[18]

Bardelli’s studies are changing the landscape of precision medicine and his discoveries have been reported in high peer-reviewed scientific journals as Cancer Cell, Nature, JAMA, and Lancet Oncology.

Currently, Bardelli’s team use colorectal cancer models to establish a personalized treatment for patients, focusing on:

- molecular heterogeneity and clonal evolution, both inter-patient and intra-tumour, to overcome the resistance to targeted therapies;

- immunotherapy to manipulate the patient’s immune system and to find new therapeutic options;

Bardelli’s team is composed of more than 20 member including biologists, PH students, technicians and bioinformatics.

Citations

Bardelli has authored more than 200 scientific articles of which 100 as an independent investigator. His research papers have been cited over 40,000 times.[19] Bardelli has been listed as Highly Cited Researcher in the field of Clinical Medicine in Clarivate Web of Science (2014, 2018-2020).[20]

Awards

2021 ERC Advaced Grant

2020 Guido Venosta Award, FIRC AIRC, Presidenza della Repubblica Italiana

2019 Elected Member of the Johns Hopkins Society of Scholars[21]

2017 ESMO Translational Research Award

2017 Fellow of European Molecular Biology Organization (EMBO)

2016 Grant for Oncology Innovation Award (GOI)[22]

2015 Fellow of the European Academy of Cancer Sciences[23]

2015 Fellow of the Turin Academy of Sciences[24]

2004 The Alfred Blalock Research Award - Johns Hopkins Medical School, Baltimore USA[25]

1996 Cecilia Cioffrese -Cancer Research Award, Carlo Erba Foundation

1994 Francesca e Ferdinando Quartero, Cancer Research Prize, Italian Cancer Association

1994 VIII Mascia Brunelli-Award, Italian Cell Culture Association

Honours

Bardelli was appointed “Officer" of the Order of Merit of the Italian Republic in 2021.

References

  1. ↑ Torino, Università degli Studi di. "Prof. Alberto Bardelli". Dipartimento di Oncologia (in italiano). Retrieved 2021-05-14.
  2. ↑ "IFOM Alberto Bardelli". www.ifom.eu. Retrieved 2021-05-14.
  3. ↑ "Tutti i membri". www.airc.it (in italiano). Retrieved 2021-05-14.
  4. ↑ Bardelli, Alberto; Parsons, D. Williams; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Saha, Saurabh; Markowitz, Sanford; Willson, James K. V.; Parmigiani, Giovanni; Kinzler, Kenneth W.; Vogelstein, Bert (2003-05-09). "Mutational analysis of the tyrosine kinome in colorectal cancers". Science. 300 (5621): 949. doi:10.1126/science.1082596. ISSN 1095-9203. PMID 12738854.
  5. ↑ Siravegna, Giulia; Lazzari, Luca; Crisafulli, Giovanni; Sartore-Bianchi, Andrea; Mussolin, Benedetta; Cassingena, Andrea; Martino, Cosimo; Lanman, Richard B.; Nagy, Rebecca J.; Fairclough, Stephen; Rospo, Giuseppe (2018-07-09). "Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer". Cancer Cell. 34 (1): 148–162.e7. doi:10.1016/j.ccell.2018.06.004. ISSN 1878-3686. PMID 29990497.
  6. ↑ Siravegna, Giulia; Mussolin, Benedetta; Buscarino, Michela; Corti, Giorgio; Cassingena, Andrea; Crisafulli, Giovanni; Ponzetti, Agostino; Cremolini, Chiara; Amatu, Alessio; Lauricella, Calogero; Lamba, Simona (July 2015). "Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients". Nature Medicine. 21 (7): 795–801. doi:10.1038/nm.3870. ISSN 1546-170X. PMC 4868598. PMID 26030179.
  7. ↑ Van Emburgh, Beth O.; Sartore-Bianchi, Andrea; Di Nicolantonio, Federica; Siena, Salvatore; Bardelli, Alberto (2014-09-12). "Acquired resistance to EGFR-targeted therapies in colorectal cancer". Molecular Oncology. 8 (6): 1084–1094. doi:10.1016/j.molonc.2014.05.003. ISSN 1878-0261. PMC 5528615. PMID 24913799.
  8. ↑ Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice (January 2016). "Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer". Cancer Discovery. 6 (1): 36–44. doi:10.1158/2159-8290.CD-15-0940. ISSN 2159-8290. PMID 26546295.
  9. ↑ Russo, Mariangela; Lamba, Simona; Lorenzato, Annalisa; Sogari, Alberto; Corti, Giorgio; Rospo, Giuseppe; Mussolin, Benedetta; Montone, Monica; Lazzari, Luca; Arena, Sabrina; Oddo, Daniele (2018-06-12). "Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies". Nature Communications. 9 (1): 2287. Bibcode:2018NatCo...9.2287R. doi:10.1038/s41467-018-04506-z. ISSN 2041-1723. PMC 5997733. PMID 29895949.
  10. ↑ Arena, Sabrina; Siravegna, Giulia; Mussolin, Benedetta; Kearns, Jeffrey D.; Wolf, Beni B.; Misale, Sandra; Lazzari, Luca; Bertotti, Andrea; Trusolino, Livio; Adjei, Alex A.; Montagut, Clara (2016-02-03). "MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations". Science Translational Medicine. 8 (324): 324ra14. doi:10.1126/scitranslmed.aad5640. hdl:10230/26180. ISSN 1946-6242. PMID 26843189.
  11. ↑ Misale, Sandra; Bozic, Ivana; Tong, Jingshan; Peraza-Penton, Ashley; Lallo, Alice; Baldi, Federica; Lin, Kevin H.; Truini, Mauro; Trusolino, Livio; Bertotti, Andrea; Di Nicolantonio, Federica (2015-09-22). "Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers". Nature Communications. 6: 8305. Bibcode:2015NatCo...6.8305M. doi:10.1038/ncomms9305. ISSN 2041-1723. PMC 4595628. PMID 26392303.
  12. ↑ Medico, Enzo; Russo, Mariangela; Picco, Gabriele; Cancelliere, Carlotta; Valtorta, Emanuele; Corti, Giorgio; Buscarino, Michela; Isella, Claudio; Lamba, Simona; Martinoglio, Barbara; Veronese, Silvio (2015-04-30). "The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets". Nature Communications. 6: 7002. Bibcode:2015NatCo...6.7002M. doi:10.1038/ncomms8002. ISSN 2041-1723. PMID 25926053.
  13. ↑ Siravegna, Giulia; Marsoni, Silvia; Siena, Salvatore; Bardelli, Alberto (September 2017). "Integrating liquid biopsies into the management of cancer". Nature Reviews. Clinical Oncology. 14 (9): 531–548. doi:10.1038/nrclinonc.2017.14. ISSN 1759-4782. PMID 28252003.
  14. ↑ Siravegna, Giulia; Bardelli, Alberto (March 2016). "Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients". Molecular Oncology. 10 (3): 475–480. doi:10.1016/j.molonc.2015.12.005. ISSN 1878-0261. PMC 5528968. PMID 26774880.
  15. ↑ Siravegna, Giulia; Bardelli, Alberto (March 2016). "Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients". Molecular Oncology. 10 (3): 475–480. doi:10.1016/j.molonc.2015.12.005. ISSN 1878-0261. PMC 5528968. PMID 26774880.
  16. ↑ Bardelli, Alberto; Pantel, Klaus (2017-02-13). "Liquid Biopsies, What We Do Not Know (Yet)". Cancer Cell. 31 (2): 172–179. doi:10.1016/j.ccell.2017.01.002. ISSN 1878-3686. PMID 28196593.
  17. ↑ Bardelli, Alberto (2017-05-24). "Medical research: Personalized test tracks cancer relapse". Nature. 545 (7655): 417–418. Bibcode:2017Natur.545..417B. doi:10.1038/545417a. ISSN 1476-4687. PMID 28541318.
  18. ↑ Germano, Giovanni; Lamba, Simona; Rospo, Giuseppe; Barault, Ludovic; Magrì, Alessandro; Maione, Federica; Russo, Mariangela; Crisafulli, Giovanni; Bartolini, Alice; Lerda, Giulia; Siravegna, Giulia (2017-12-07). "Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth". Nature. 552 (7683): 116–120. Bibcode:2017Natur.552..116G. doi:10.1038/nature24673. ISSN 1476-4687. PMID 29186113.
  19. ↑ "Scopus preview - Bardelli, Alberto - Author details - Scopus". www.scopus.com. Retrieved 2021-05-14.
  20. ↑ "Alberto Bardelli's Publons profile". publons.com. Retrieved 2021-05-14.
  21. ↑ April 10, Hub staff report / Published; 2019 (2019-04-10). "Johns Hopkins inducts new members into Society of Scholars". The Hub. Retrieved 2021-05-14.{{cite web}}: CS1 maint: numeric names: authors list (link)
  22. ↑ "Home | EMD Serono". www.emdserono.com. Retrieved 2021-05-14.
  23. ↑ "Fellows| European Academy of Cancer Sciences". www.europeancanceracademy.eu. Retrieved 2021-05-14.
  24. ↑ "II sezione: scienze della biologia animale e dell'uomo". www.accademiadellescienze.it. Retrieved 2021-05-14.
  25. ↑ Simpkins, Beth. "2004 Young Investigator's Day Winners". www.hopkinsmedicine.org. Retrieved 2021-05-14.

External links

Add External links

This article "Alberto Bardelli" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.

Retrieved from "https://wikitia.com/index.php?title=Alberto_Bardelli&oldid=106528"